38 days ago
On 24 August 2026 as Skinbiotherapeutics (SBTX) appointed a new interim CFO to replace the hapless Emily Bertram it stated “The Company is in advanced discussions with potential NED candidates and looks forward to updating the market in due course, and is also intending to issue a business update by mid-September which will include further Board updates.”
119 days ago
"You are not answering the f*cking question" I screamed at my screen as Alyson Levett failed to answer one of the questions I posed. Up until that point I was really quite impressed. So what are the key takeaways from today’s Investor Meet event.
123 days ago
First it was the prolific liar and fraudster Stuart Ashman, then the incompetent chairman Martin Hunt and now I have a third scalp: Emily Bertram who was appointed as CFO in April 2025 and joined the board in January 2026 has resigned from Skinbiotherapeutics (SBTX) and will leave the company next Tuesday. Another head I demanded has rolled.
151 days ago
As I have noted many times, to hoots of derision from small furry rodents, Stuart Ashman’s fanboys and other denialists, if the only matter being investigated by FRP at Skinbiotherapeutics (SBTX) was the fraudulent recognition of accrued income from Croda, thus investigation which started in mid February would have been over by March. Today we have an update.
192 days ago
A few readers pose the question. Shares in Skinbiotherapeutics (SBTX) have now been suspended for almost three weeks as a result of it not being able to get out its accounts for the six months to December 31 while enquiries continue into the fraudulent June 2025 numbers. But why is this taking so long?
323 days ago
Skinbiotherapeutics (SBTX) insists that it follows the QCA code of corporate governance. But like so much else it says that is simply not true. Now I add to Stuart Ashman’s growing rap sheet a charge of cowardice.
324 days ago
Laughably Stuart Ashman of Skinbiotherpeutics (SBTX) yesterday praised his bean counter Emily Bertram for her good work and said she’d be promoted for that good work (ching ching for young Emily) in January. This came on a day when June 2025 results finally emerged and contain two material breaches of IFRS. And Emily is being praised and rewarded for her blunders? I have written to my good pals at the FRC…
550 days ago
Folks like the Lemming thought that Skinbiotherapeutics (SBTX) FD Manprick Randhawa was the bees knees and were jolly cross with me for rebranding him for his patent incompetence. In my view he was useless, unable to communicate with serious investors or to stop Stuart Ashman abusing the word accretive and, at least, partially responsible for the cack handed and dilutive financing of two acquisitions. He was unable to control costs. Well, today, he has gone to pursue other business interests. Great news.. It has prompted me to buy more shares, increasing my holding by 25%.
